KR20190142424A - 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성 - Google Patents

기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성 Download PDF

Info

Publication number
KR20190142424A
KR20190142424A KR1020197037186A KR20197037186A KR20190142424A KR 20190142424 A KR20190142424 A KR 20190142424A KR 1020197037186 A KR1020197037186 A KR 1020197037186A KR 20197037186 A KR20197037186 A KR 20197037186A KR 20190142424 A KR20190142424 A KR 20190142424A
Authority
KR
South Korea
Prior art keywords
cells
platelets
medium
megakaryocytes
tpo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197037186A
Other languages
English (en)
Korean (ko)
Inventor
펭 리
쉬-지앙 루
Original Assignee
스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. filed Critical 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크.
Priority to KR1020217016080A priority Critical patent/KR20210066020A/ko
Publication of KR20190142424A publication Critical patent/KR20190142424A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2311—Interleukin-11 (IL-11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197037186A 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성 Ceased KR20190142424A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217016080A KR20210066020A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26693909P 2009-12-04 2009-12-04
US61/266,939 2009-12-04
US38416510P 2010-09-17 2010-09-17
US61/384,165 2010-09-17
PCT/US2010/058990 WO2011069127A1 (en) 2009-12-04 2010-12-03 Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187021160A Division KR20180086301A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217016080A Division KR20210066020A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성

Publications (1)

Publication Number Publication Date
KR20190142424A true KR20190142424A (ko) 2019-12-26

Family

ID=44115332

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197037186A Ceased KR20190142424A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
KR1020127017368A Ceased KR20120128605A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
KR1020217016080A Ceased KR20210066020A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
KR1020187021160A Ceased KR20180086301A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020127017368A Ceased KR20120128605A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
KR1020217016080A Ceased KR20210066020A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
KR1020187021160A Ceased KR20180086301A (ko) 2009-12-04 2010-12-03 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성

Country Status (10)

Country Link
US (2) US9988603B2 (enExample)
EP (1) EP2507359A4 (enExample)
JP (4) JP2013512676A (enExample)
KR (4) KR20190142424A (enExample)
AU (4) AU2010325811A1 (enExample)
BR (1) BR112012013497A2 (enExample)
CA (2) CA2782013C (enExample)
IN (1) IN2012DN05054A (enExample)
RU (1) RU2012127810A (enExample)
WO (1) WO2011069127A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712258B1 (en) 2006-04-14 2025-01-01 Astellas Institute for Regenerative Medicine Hemangio-colony forming cells
KR20190142424A (ko) 2009-12-04 2019-12-26 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
KR102108245B1 (ko) 2011-11-30 2020-05-08 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
EP3973967A1 (en) * 2012-12-21 2022-03-30 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
JP6580329B2 (ja) 2014-03-31 2019-09-25 シスメックス株式会社 未分化細胞から分化細胞および／または分化細胞の産生物を取得する方法
WO2015179301A1 (en) 2014-05-19 2015-11-26 Eleftherios Papoutsakis Megakaryocytic particles and microparticles for cell therapy & fate modification of stem and progenitor cells
AU2016242823A1 (en) * 2015-03-30 2017-09-21 Jeffrey Thomas Loh Methods for producing modified red blood cell compositions, compositions and uses thereof
AU2016308818B2 (en) 2015-08-18 2022-04-21 Astellas Institute For Regenerative Medicine Clinical formulations
CN108135940B (zh) * 2015-10-14 2022-04-15 株式会社美加细胞 纯化血小板的制造方法
MX2020007071A (es) 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
CA3178268A1 (en) 2020-05-11 2021-11-18 Jonathan Thon Compositions and methods related to megakaryocyte-derived extracellular vesicles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128259A (en) 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
EP1364197B1 (en) * 2001-01-29 2010-04-14 Ivan N. Rich ATP-based assay for the determination of the proliferation status of hematopoietic stem and progenitor cells
WO2002078449A2 (en) 2001-04-02 2002-10-10 Advanced Cell Technology, Inc. Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
WO2003046141A2 (en) 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US20040052771A1 (en) 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
US20040229350A1 (en) 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
CN1286970C (zh) 2003-12-30 2006-11-29 上海伯瑞生物技术发展有限公司 由脐血cd34+细胞体外诱导生成巨核细胞的方法
EP1735429A4 (en) 2004-03-31 2008-06-11 Newlink Genetics Corp METHOD AND COMPOSITIONS FOR OBTAINING EMBRYONAL STEM CELLS OF ABSTINENT HEMATOPOETIC STEM CELLS AND USES THEREOF
WO2006050330A2 (en) * 2004-11-01 2006-05-11 Wisconsin Alumni Research Foundation Platelets from stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
WO2007095064A2 (en) 2006-02-09 2007-08-23 Wisconsin Alumni Research Foundation ERYTHROID CELLS PRODUCING ADULT-TYPE β-HEMOGLOBIN GENERATED FROM HUMAN EMBRYONIC STEM CELLS
CN101045914A (zh) 2006-03-29 2007-10-03 中国人民解放军军事医学科学院野战输血研究所 体外诱导造血干/祖细胞分化为成熟红细胞的方法与应用
EP3712258B1 (en) * 2006-04-14 2025-01-01 Astellas Institute for Regenerative Medicine Hemangio-colony forming cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9683232B2 (en) * 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
EP3441462A1 (en) 2008-05-06 2019-02-13 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
CN112280739A (zh) 2008-05-06 2021-01-29 安斯泰来再生医药协会 用于制备衍生自多能干细胞的去核类红细胞的方法
KR20190142424A (ko) 2009-12-04 2019-12-26 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성

Also Published As

Publication number Publication date
US9988603B2 (en) 2018-06-05
EP2507359A1 (en) 2012-10-10
JP2016135138A (ja) 2016-07-28
AU2017201995B2 (en) 2019-06-06
CA2782013A1 (en) 2011-06-09
US20120315338A1 (en) 2012-12-13
KR20180086301A (ko) 2018-07-30
KR20210066020A (ko) 2021-06-04
US20190002829A1 (en) 2019-01-03
RU2012127810A (ru) 2014-01-10
AU2022200188A1 (en) 2022-02-10
IN2012DN05054A (enExample) 2015-10-09
WO2011069127A1 (en) 2011-06-09
KR20120128605A (ko) 2012-11-27
AU2019203670B2 (en) 2021-10-14
JP2022064953A (ja) 2022-04-26
EP2507359A4 (en) 2015-05-13
CA3115233A1 (en) 2011-06-09
AU2010325811A1 (en) 2012-06-21
JP2013512676A (ja) 2013-04-18
AU2019203670A1 (en) 2019-06-13
BR112012013497A2 (pt) 2016-05-31
AU2017201995A1 (en) 2017-04-13
CA2782013C (en) 2021-06-08
JP2019122385A (ja) 2019-07-25

Similar Documents

Publication Publication Date Title
US20250099505A1 (en) Methods for production of platelets from pluripotent stem cells and compositions thereof
AU2019203670B2 (en) Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
US20200263132A1 (en) Methods for producing enucleated erythroid cells derived from pluripotent stem cells
US20200157503A1 (en) Hemangio colony forming cells and non-engrafting hemangio cells
US20110151554A1 (en) Method for culturing and subculturing primate embryonic stem cell, as well as method for inducing differentiation thereof
US20120295347A1 (en) Methods and Compositions for Producing Endothelial Progenitor Cells from Pluripotent Stem Cells
WO2005097979A2 (en) Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
Marshall The origin and regulation of haematopoietic stem cells during mammalian embryogenesis
WO2012103098A2 (en) Compositions and methods for treating hematological cytopenias

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191216

Application number text: 1020187021160

Filing date: 20180723

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200131

Patent event code: PE09021S01D

AMND Amendment
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20200810

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200131

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201030

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200331

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210224

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210129

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20201030

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200331

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200131

X601 Decision of rejection after re-examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210526

Application number text: 1020187021160

Filing date: 20180723